140 related articles for article (PubMed ID: 33360667)
1. "More men die with prostate cancer than because of it" - an old adage that still holds true in the 21st century.
C J; Y P; Sf B; Rj B
Cancer Treat Res Commun; 2021; 26():100225. PubMed ID: 33360667
[TBL] [Abstract][Full Text] [Related]
2. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Schmanke K; Okut H; Ablah E
Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma.
Misraï V; Pasquie M; Bordier B; Guillotreau J; Gryn A; Palasse J; Bruguière E; Pradere B; Rouprêt M; Zorn KC
World J Urol; 2020 Apr; 38(4):993-1000. PubMed ID: 31139906
[TBL] [Abstract][Full Text] [Related]
4. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
5. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
Choi H; Cho S; Bae JH; Lee SE; Hong SK; Moon DG; Cheon J; Byun SS; Park JY
Urol Int; 2017; 99(2):143-148. PubMed ID: 28395285
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men.
Zlotta AR; Egawa S; Pushkar D; Govorov A; Kimura T; Kido M; Takahashi H; Kuk C; Kovylina M; Aldaoud N; Fleshner N; Finelli A; Klotz L; Sykes J; Lockwood G; van der Kwast TH
J Natl Cancer Inst; 2013 Jul; 105(14):1050-8. PubMed ID: 23847245
[TBL] [Abstract][Full Text] [Related]
8. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
9. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
[TBL] [Abstract][Full Text] [Related]
10. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
11. Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Wyler SF; Chun FF; Recker F; Kwiatkowski M
World J Urol; 2015 Aug; 33(8):1189-96. PubMed ID: 25358675
[TBL] [Abstract][Full Text] [Related]
12. Prevelance of prostate cancer among Turkish men with prostate-specific antigen level of ≤100 ng/ml.
Çalışkan S
J Cancer Res Ther; 2018; 14(6):1256-1259. PubMed ID: 30488840
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
14. Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.
Shahangian S; Fan L; Sharma KP; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1352. PubMed ID: 33932150
[TBL] [Abstract][Full Text] [Related]
15. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
Shahangian S; Sharma KP; Fan L; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1365. PubMed ID: 33934557
[TBL] [Abstract][Full Text] [Related]
16. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.
Cosma G; McArdle SE; Foulds GA; Hood SP; Reeder S; Johnson C; Khan MA; Pockley AG
Front Immunol; 2021; 12():786828. PubMed ID: 34975879
[TBL] [Abstract][Full Text] [Related]
18. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
[TBL] [Abstract][Full Text] [Related]
19. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
